Revolution Medicines CFO Executes 10b5-1 Trades; Retains 113,314 Shares

Rhea-AI Filing Summary

Revolution Medicines CFO Jack Anders reported multiple transactions under a 10b5-1 plan on September 2-3, 2025. The filings show option exercises and open-market sales and purchases: Mr. Anders exercised stock options at strike prices of $2.68, $4.73 and $17 and acquired 9,200 shares through option exercises and purchase transactions at prices between $2.68 and $17. He sold a total of 10,000 shares in multiple trades at weighted-average sale prices of approximately $40.02 and $40.1742. After these transactions he beneficially owned 113,314 shares (which include 54,213 RSUs) and held stock options exercisable into 15,418 shares. The transactions were made pursuant to a 10b5-1 trading plan adopted December 16, 2024.

Positive

• Transactions executed under a 10b5-1 plan, indicating pre-approved, rule-compliant trading
• Executive retains significant equity exposure: 113,314 shares beneficially owned after trades, including 54,213 RSUs
• Maintained option holdings: stock options exercisable into 15,418 shares remain outstanding

Negative

• Insider sold 10,000 shares in open-market transactions at weighted-average prices around $40, reducing immediate holdings
• Large sales executed at market prices (ranges up to $40.32) could be perceived negatively by some investors seeking pure insider buying signals

Insights

Securities Analyst

TL;DR: Insider exercised options and executed planned sales under a 10b5-1 plan; post-trade ownership remains meaningfully positive.

Mr. Anders executed and acquired shares via option exercises at low strike prices and concurrently sold 10,000 shares in multiple trades at ~ $40 per share under a 10b5-1 plan. The combination of low-strike exercises and sales is typical tax/liquidity activity for executives. He still beneficially owns 113,314 shares, including 54,213 RSUs, and retains options convertible into 15,418 shares, preserving continued alignment with shareholders while realizing liquidity.

Corporate Governance Expert

TL;DR: Transactions were executed under a documented 10b5-1 plan, demonstrating procedural compliance with insider trading rules.

The filing explicitly states the trades were made pursuant to a 10b5-1 plan adopted December 16, 2024, and provides weighted-average sale-price ranges for the dispositions. Documentation and footnotes committing to provide execution details on request improve transparency. The insider retains substantial equity and option exposure after the trades, which mitigates immediate governance concerns about alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		M(1)		2,814	A	$2.68	116,128(2)	D
Common Stock	09/02/2025		M(1)		1,948	A	$4.73	118,076(2)	D
Common Stock	09/02/2025		S(1)		4,762	D	$40.0168(3)	113,314(2)	D
Common Stock	09/03/2025		M(1)		3,189	A	$4.73	116,503(2)	D
Common Stock	09/03/2025		M(1)		2,049	A	$17	118,552(2)	D
Common Stock	09/03/2025		S(1)		5,238	D	$40.1742(4)	113,314(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.68	09/02/2025		M(1)			2,814	08/16/2022	09/26/2028	Common Stock	2,814	$0	0	D
Stock Option (Right to Buy)	$4.73	09/02/2025		M(1)			1,948	08/09/2023	08/08/2029	Common Stock	1,948	$0	3,189	D
Stock Option (Right to Buy)	$4.73	09/03/2025		M(1)			3,189	08/09/2023	08/08/2029	Common Stock	3,189	$0	0	D
Stock Option (Right to Buy)	$17	09/03/2025		M(1)			2,049	02/12/2024	02/11/2030	Common Stock	2,049	$0	15,418	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.

2. Includes 54,213 RSUs.

3. This transaction was executed in multiple trades in prices ranging from $40.00 to $40.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. This transaction was executed in multiple trades in prices ranging from $40.01 to $40.32, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

	/s/ Jack Anders	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Revolution Medicines (RVMD) CFO Jack Anders report on Form 4?

The Form 4 reports option exercises, purchases and open-market sales executed on 09/02/2025 and 09/03/2025, including acquisitions via exercises at strikes of $2.68, $4.73 and $17 and sales totaling 10,000 shares.

Were the sales by Jack Anders planned or discretionary?

The filing states the transactions were made pursuant to a 10b5-1 trading plan adopted December 16, 2024.

How many shares does Jack Anders beneficially own after the reported transactions?

After the reported transactions he beneficially owns 113,314 common shares, which include 54,213 RSUs.

Does Jack Anders still hold options after these transactions and how many?

Yes. The Form 4 shows stock options exercisable into 15,418 common shares remain outstanding following the transactions.

At what prices were the sold shares executed?

Footnotes state the sales were executed in multiple trades with weighted-average sale prices reported as approximately $40.0168 and $40.1742, with trade ranges from $40.00 to $40.32.